Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral treprostinil Clear all
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2010 · Synced Sep 8, 2026, 3:50 PM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Remodulin® to Oral Treprostinil Transition

NCT01588405
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
UT-15C SR
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
15 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

NCT01560637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
UT-15C (treprostinil diolamine)
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

NCT00887978
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C SR, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Sep 8, 2026, 3:50 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions
L606, Placebo
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Early Phase 1 Interventional

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

NCT02583789
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
oral treprostinil, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 8, 2026, 3:50 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Fresno, California • Torrance, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 8, 2026, 3:50 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Oral Treprostinil in Digital Ulcers

NCT00848107
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

NCT01172496
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 8, 2026, 3:50 PM EDT
Terminated Phase 4 Interventional Results available

Treprostinil Combined With Tadalafil for Pulmonary Hypertension

NCT01302444
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on the Pharmacokinetics of Oral Treprostinil

NCT00963001
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Standardized meals
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

NCT00848939
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

NCT01131845
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Renal Dysfunction
Interventions
UT-15C SR (treprostinil diethanolamine)
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

NCT06091579
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 8, 2026, 3:50 PM EDT
Withdrawn Phase 2 Interventional

Telemonitoring to Treat Group 2 Pulmonary Hypertension

NCT04882774
View directory record Official record
Conditions
Pulmonary Hypertension Due to Left Heart Disease
Interventions
Treprostinil Diolamine
Drug
Lead sponsor
Mardi Gomberg -Maitland MD, MSc
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 8, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

NCT02276872
View directory record Official record
Conditions
PAH
Interventions
oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 8, 2026, 3:50 PM EDT
Recruiting Phase 3 Interventional

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Naples, Florida • Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 8, 2026, 3:50 PM EDT
Recruiting Phase 4 Interventional

Open Label Treprostinil Raynaud's Study

NCT07112183
View directory record Official record
Conditions
Raynaud's Disease, Raynaud Phenomena, Raynauds
Interventions
Oral treprostinil (UT-15C) sustained release tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 8, 2026, 3:50 PM EDT